If your email program has trouble displaying this email, view as a webpage.

FDA Announces Expansion of the Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot

Today, the U.S. Food and Drug Administration (FDA) is announcing that beginning October 1, 2023, the TAP Pilot will expand to include devices in the Office of Neurological and Physical Medicine (OHT5). TAP is intended to help ensure that U.S. patients have access to high-quality, safe, effective, and innovative medical devices first in the world for years to come by promoting early, frequent, and strategic communications between the FDA and medical device sponsors.

Questions?

If you have questions about the voluntary TAP Pilot, email TPLC-Advisory-Program@fda.hhs.gov.